Small-Cap Snapshot: Sage rallies as postpartum depression treatment shows promise in clinical trial

AxoGen and NuVasive fall after reporting preliminary revenue figures trailing the consensus of analysts

An illustration of depression
In June, the FDA allowed Sage to expedite development of its postpartum depression treatment

SAGE Therapeutics Inc (NASDAQ:SAGE) rallied after the Cambridge, Massachusetts-based company said its postpartum depression treatment has shown promise in a clinical trial. After two weeks of outpatient treatment, patents showed statistically significant improvement on a rating scale for depression, according to Sage. In June, the Food and Drug Administration allowed the company to expedite development of its SAGE-217 treatment.

Shares rallied $39.62, or 41%, to $137.13.

READ: SAGE Therapeutics shares rocket after FDA clearance to expedite its depression post-partum drug

QEP Resources Inc (NYSE:QEP) gained as the Denver-based crude oil and natural gas exploration and production company confirmed that it had received a preliminary proposal from Elliott Management Corp to acquire the company for $8.75 per share in cash. QEP said its board intends to review the hedge fund's proposal and will consider the proposal in the context of the best interests of all shareholders. The board plans to take into account the company's other alternatives as well as current market conditions. QEP primarily operates in Texas, Louisiana and North Dakota.

Shares surged $2.49, or 41%, to $8.57.

AxoGen Inc (NASDAQ:AXGN) fell after publishing preliminary fourth-quarter revenue of $23.4 million, up 38% from a year earlier but less than the analyst consensus of $24.2 million. The Alachua, Florida-based company develops and markets surgical products for peripheral nerve injuries. AxoGen expects 2018 revenue of $83.9 million, up 39% from the prior year.

Shares declined $4.69, or 22%, to $16.59.

NuVasive Inc (NASDAQ:NUVA) dropped after reporting preliminary fourth-quarter revenue of about $288 million, less than the analyst consensus of $294 million. The San Diego company developer of spine surgery technology expects 2018 revenue of about $1.1 billion, up 7% from the prior year.

The stock decreased $3.94, or 7.9%, to $46.08.

The Russell 2000 index of small-cap stocks advanced 1.9% to 1,407.28 on Monday.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Great Bear Resources releases more positive drill results...

Great Bear Resources (CVE: GBR) President and CEO Chris Taylor joined Steve Darling from Proactive Vancouver to discuss their latest assay results from the drill program on the Dixie Project in Red Lake.  Taylor discusser the results from the Hinge and Dixie Limb zones and also gave...

18 hours, 42 minutes ago

2 min read